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Military veterans may have higher rates of amyotrophic lateral sclerosis (ALS) mortality than
non-veterans. Few studies, with sparse exposure information and mixed results, have stud-
ied relationships between military-related factors and ALS survival. We evaluated associa-
tions between military-related factors and ALS survival among U.S. military veteran cases.
Methods
We followed 616 medical record-confirmed cases from enrollment (2005–2010) in the
Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis study
until death or July 25, 2013, whichever came first. We ascertained vital status information
from several sources within the Department of Veterans Affairs. We obtained information
regarding military service, deployments, and 39 related exposures via standardized tele-
phone interviews. We used Cox proportional hazards regression models to estimate hazard
ratios (HRs) and 95% confidence intervals. We adjusted for potential confounding and miss-
ing covariate data biases via inverse probability weights. We also used inverse probability
weights to adjust for potential selection bias among a case group that included a dispropor-
tionate number of long-term survivors at enrollment.
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Results
We observed 446 deaths during 24,267 person-months of follow-up (median follow-up: 28
months). Survival was shorter for cases who served before 1950, were deployed to World
War II, or mixed and applied burning agents, with HRs between 1.58 and 2.57. Longer sur-
vival was associated with exposure to: paint, solvents, or petrochemical substances; local
food not provided by the Armed Forces; or burning agents or Agent Orange in the field with
HRs between 0.56 and 0.73.
Conclusions
Although most military-related factors were not associated with survival, associations we
observed with shorter survival are potentially important because of the large number of mili-
tary veterans.
Introduction
Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disease of motor neu-
rons in the central nervous system [1]. Median survival after diagnosis is three years, but 4% of
cases survive past 10 years [1]. Factors consistently associated with rapid progression or
shorter survival include older diagnosis age [2–5], bulbar onset [2–6], clinical features (e.g.,
worse functional/disability status) [2, 3], shorter diagnostic delay [2, 5, 6], and definite diagno-
sis category [2]. Few studies, however, have considered non-clinical (e.g., occupational or envi-
ronmental) prognostic factors for ALS survival, but these factors could help explain the
extremely heterogeneous survival of ALS patients. In addition, identifying associations
between non-clinical factors and ALS survival could help clinicians target interventions that
may have the potential to lengthen survival, such as interdisciplinary palliative care [2], to
patients at greatest risk of shorter survival.
Limited evidence suggests ALS rates may be higher among military veterans, particularly
those deployed to the 1990–1991 Persian Gulf War (hereafter “Gulf War”) [7–10]. The few
studies that examined associations between military-related factors and ALS survival or pro-
gression [5, 6, 11, 12] conflict and contain sparse exposure information. A study of the ALS
Clinical Assessment, Research and Education database, a non-military database of North
American patients [13], found no association between veteran status and survival [11],
whereas a study in Massachusetts reported being a male veteran was associated with faster pro-
gression after one year of follow-up [6]. Deployment to the Gulf War was associated with
shorter survival in one study [12], but not another [5]. The latter, based on the U.S. National
Registry of Veterans with ALS (hereafter “Registry”) [14], also found shorter survival was asso-
ciated with deployment to Vietnam, but not with cumulative military service, service branch,
or deployment to Korea [5]. We evaluated associations between ALS survival and aspects of
military service, deployments, and 39 related exposures using additional data on a subset of
Registry cases enrolled in the Genes and Environmental Exposures in Veterans with Amyotro-
phic Lateral Sclerosis study (GENEVA) [15].
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Materials and methods
Study population and outcome assessment
GENEVA is a case-control study of veterans, conducted from 2005–2010, that includes ALS
cases from the Registry [14] and controls identified via U.S. Department of Veterans Affairs
(VA) databases [15]. Although participants did not have to have been deployed to war to enroll
in GENEVA, they did have to have been members of the U.S. Army, Air Force, Navy, Marine
Corps, Coast Guard, activated Reserves or National Guard at some point in time [16, 17]. We
previously used data on GENEVA cases and controls to evaluate associations between mili-
tary-related factors and ALS etiology [17]. The present analysis focused on ALS survival and
included cases only.
Methods used to enroll cases first in the Registry, then in GENEVA, were published previ-
ously [14, 15]. Briefly, the VA started the Registry because of increased ALS rates among veter-
ans who had been deployed to the Gulf War [14, 15, 18]. Recruitment of potential cases
occurred from 2003 to 2007 (i.e., the year the original Gulf War ALS studies [9, 10] were pub-
lished to when funding expired) and included searches of national VA databases for patients
with International Classification of Diseases, 9th Revision [19], codes of the form 335.2X (motor
neuron diseases) and publicizing the Registry [14]. In total, there were 7,116 potential cases
identified, 4,626 who completed a telephone screening [16], and 2,600 who reported a past
diagnosis [14]. Of these, there were 2,400 who consented to join, 2,265 who allowed their med-
ical records to be reviewed by ALS specialist neurologists, and 2,122 who had a diagnosis of
ALS or another motor neuron disease confirmed using the Revised El Escorial Criteria [14,
20]. These 2,122 cases were followed until 2009 via standardized semi-annual telephone inter-
views [17].
The ascertainment of GENEVA cases from the Registry is shown in Fig 1. Of 1,856 ALS
cases, there were 1,837 who gave permission to be re-contacted for further studies, 1,356 who
consented to join the Registry DNA bank, and 847 who were able to be contacted regarding
GENEVA enrollment. Of these, there were 726 who consented to join and 630 who enrolled,
of which we included 616 in this analysis because they had information on diagnosis date and
were not enrolled posthumously by proxy. These cases were comprised of patients with clini-
cally definite, probable, possible, or suspected ALS.
The outcome we used was days from diagnosis date to death date or end of follow-up (July
25, 2013), with late entry at GENEVA enrollment date. Time since diagnosis was the most clin-
ically meaningful time scale and allowing for late entry at enrollment date addressed potential
immortal person-time bias, which occurs when follow-up time that occurs before the last
event required to enter the study is counted as person-time at risk for death [21], from left
truncation. Time to death is recommended over other ALS survival outcomes (e.g., time to use
of ventilator or death), which are not uniformly defined or used across centers [22].
We extracted information on diagnosis date from medical records [16]. We obtained vital
status information from the Austin Vital Status File, which contains information from several
sources within the VA [23]. Using the National Death Index [24] as the gold standard, a valida-
tion study found the Austin Vital Status File was 98.3% sensitive and 99.8% specific (κ = 0.981)
for identifying deaths among veterans [23]. Thus, it is likely we missed only a small proportion
of deaths among GENEVA cases.
The Institutional Review Boards (IRBs) of the Durham VA Medical Center, Duke Univer-
sity Medical Center, and the National Institute of Environmental Health Sciences approved
GENEVA; this ancillary study was approved by the IRB of the University of North Carolina at
Chapel Hill. All participants provided written or oral informed consent before enrollment,
which we tracked via Microsoft Access databases and documented by maintaining copies of
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signed informed consent forms. We also mailed copies of informed consent forms to each par-
ticipant. For the Registry, oral informed consent was sought and approved by the IRB of the
Durham VA Medical Center when participants were unable to provide written informed con-
sent due to the progression of their disease. For GENEVA, oral informed consent was sought
Fig 1. Flow chart showing the ascertainment of GENEVA cases, United States of America, 2005–2010. Solid boxes or lines
depict cases who progressed past each step shown. Small-dashed boxes or lines depict cases who did not progress past each
step shown, but who were incorporated into the analysis indirectly via inverse probability weights (see Statistical Analyses and
Section C in S1 File for more details). Among the 27 cases ineligible for GENEVA, reasons included dementia (n = 9), diagnosis
change (n = 4), withdrawal from the Registry DNA bank (n = 3), or interview infeasibility (n = 11). Abbreviations: ALS, amyotrophic
lateral sclerosis; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis study; PLS,
primary lateral sclerosis.
https://doi.org/10.1371/journal.pone.0185751.g001
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and approved by the IRBs of the Durham VA Medical Center and Duke University Medical
Center for all ALS cases because the standardized telephone interview was deemed to involve
no more than minimal risk of harm to the participants.
Exposure assessment
We used medical records as the source of information on clinical features and the Registry
semi-annual telephone interviews [16] as the source of baseline (closest to GENEVA enroll-
ment) ALS Functional Rating Scale-Revised (ALSFRS-R) score [17, 25]. Standardized tele-
phone interviews for GENEVA [16] provided information on potential confounders and
military service, deployments, and exposures that occurred before diagnosis date [15]. We had
to conduct interviews via proxy for 27 (4%) cases. Interview procedures have been described
in more detail elsewhere [15].
We collected information on military service—including longest service branch (i.e., the
branch in which the veteran served the longest total time), number of branches, rank, total ser-
vice time, and end of most recent service (Section A in S1 File)—and on deployments to
World War II (WWII) and the Korean, Vietnam, and Gulf Wars (hereafter “four wars”) and
operations in nine other locations—including ever deployment to any war/operation, war/
operation of longest deployment (i.e., the war or operation to which the veteran was deployed
for the longest total time), total time of all deployments, and end of most recent deployment
[17] (Section A in S1 File). We also recorded information on ever deployment to any other
country; ever receiving imminent danger pay, hardship duty, or combat zone tax exclusion
benefits for deployment to 17 foreign countries and five sea regions (plus fill-in options); and
total time deployed to those countries/sea regions [17] (Section A in S1 File).
To identify specific military exposures, we adapted questionnaires used in the Iowa Gulf
War study [26] and the Millennium Cohort Study [27, 28] for use in GENEVA [15, 16]. We
also added a few questions on exposures that were specific to one or more of the four wars
(e.g., Agent Orange exposure during the Vietnam War) [17]. In total, we collected information
on 39 specific military exposures, 32 of which we queried only in reference to exposure during
deployment to the four wars [17], which included 16–228 cases depending on the war(s). For
the seven non-war-specific exposures, we asked cases about ever exposure and, for some expo-
sures, a quantification of exposure (e.g., number of pills) [17]. For 31 of 32 war-specific expo-
sures, we collected information on whether cases had ever been exposed, days exposed (Not
exposed, 5, 6–30,> 30), and whether they felt ill after exposure (Not exposed, No, Yes) [17].
For the other war-specific exposure, total vaccinations, we asked cases about number of shots
received [17].
Statistical analyses
We used Cox proportional hazards regression models with time since diagnosis as the time
scale to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations
between military-related factors and ALS survival. We checked the proportional hazards
assumption by evaluating the statistical significance of interactions between each covariate and
the natural logarithm of time since diagnosis [29].
We identified prognostic factors for ALS survival from previous literature to consider as
potential confounders and used directed acyclic graphs [30] to identify minimally sufficient
adjustment sets among these factors (Figure A and Section B in S1 File). For military service
and deployment factors the minimally sufficient adjustment set was age and sex and for mili-
tary exposures the minimally sufficient adjustment set was age, sex, and war/operation of
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deployment. We did not include sex in our models due to small numbers of female cases
(n = 13) and deaths (n = 10).
We calculated three types of stabilized inverse probability weights (hereafter “weights”) [31,
32], a type of propensity score, to adjust for potential bias from (1) confounding by age and
war/operation of deployment (for military exposures), (2) missing data on ALSFRS-R score
for 8% of Registry cases, and (3) selection arising from a case group that included a dispropor-
tionate number of long-term survivors at GENEVA enrollment [15] (Section C and Table A in
S1 File). Although we calculated confounding weights for each exposure separately, we used
the same missing-covariate-data and selection weights for every exposure. We assessed appro-
priateness of the weights using established criteria [31] (Section C in S1 File). We calculated
overall stabilized weights by multiplying the three types of weights together [31, 33]. We then
applied the overall stabilized weight to Cox proportional hazards regression models that con-
tained the exposure of interest as the only explanatory variable (sampling weights are applied
in the same way when analyzing data from complex survey sampling designs) [31, 33]. We
used robust variance estimates to calculate 95% CIs for the HRs because using weights for anal-
ysis induces within-subject correlation [34].
Using weights for analysis creates a pseudo-population in which there is no bias from con-
founding, missing covariate data, or selection due to measured variables that are incorporated
into the calculation of the weights [31, 32]. The weighted HRs and 95% CIs we calculated thus
generalize to the 1,786 Registry cases who: had diagnoses of clinically definite, probable, possi-
ble, or suspected ALS; were not enrolled in the Registry posthumously by proxy; had diagnosis
date available; and had no missing data on any covariates used to calculate the weights.
We used within-category medians as scores to assess linear exposure-response trends for
categorized versions of continuous variables [35] and scaled corresponding HRs to one unit or
interquartile range (IQR) increases in the original continuous variables. To assess linear trends
for days exposed to each of 31 exposures experienced during deployment to the four wars, we
used category midpoints, and 50% above the lower bound of the top category, as scores and
scaled corresponding HRs to 20-day increases. We assessed linear trends for feeling ill after
exposure to each of the same 31 exposures by using ordinal scores.
Our study is largely hypothesis-generating because most of the military-related factors we
studied have not been evaluated in relation to ALS survival by previous studies. Therefore, we
used the magnitude of associations (e.g., HRs greater than 1.25), the number of exposed ALS
deaths (e.g., five or more), and, where appropriate, evidence of exposure-response trends
rather than statistical significance to guide our choice of results to highlight in the text. How-
ever, we presented results for all military-related factors in the tables and S1 File for transpar-
ency and to stimulate further research.
Following the advice of several epidemiologists (e.g., [36–41]), we did not use conventional
multiple comparisons adjustments, such as false discovery rate [42], because our study is not
based on a random sample, does not include random exposure assignment, and assignment of
exposures cannot be thought of as approximately random [43]. In addition, hierarchical
regression models [44] were impractical for our study because of differing sample sizes avail-
able for the exposures and because it is not clear (1) how one would group the exposures, (2)
whether the assumptions made to group the exposures would be valid [45], and (3) whether
the groups would be meaningful chemically or biologically.
We performed several secondary analyses including separately analyzing war-specific expo-
sures for veterans who were deployed to the Vietnam War (64% of those with war-specific
data); the small number of veterans deployed to other wars precluded performing similar anal-
yses for them. To reduce sample heterogeneity, we separately restricted to cases who: enrolled
in GENEVA within two years of diagnosis (39%); had clinically definite or probable ALS
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(75%); or never visited or resided in western Pacific regions with high endemic ALS [1] (84%).
As an alternative way to control for confounding by age, we used age as the timescale, with late
entry at GENEVA enrollment date. To control confounding by sex, we restricted to men
(98%). We restricted to non-proxy interviews (96%) to mitigate potential bias from exposure
misclassification. In addition, we recoded implausible values to missing for four exposures
(anthrax vaccination, smallpox vaccination, nasopharyngeal radium, pyridostigmine bromide
pills) that had distinct time periods of use. We identified correlations among the 39 military
exposures by calculating Spearman correlation coefficients and then mutually-adjusted expo-
sures that were more than weakly correlated (absolute value of coefficients > 0.2). Finally, we
adjusted for potential confounding via standard regression methods, but did not weight for
potential missing-covariate-data or selection bias. We conducted all analyses using SAS ver-
sion 9.3 (SAS Institute Inc., Cary, NC, 2011).
Results
At the end of follow-up, 24,267 person-months had been observed since enrollment in
GENEVA (Table 1). Median (IQR) follow-up was 28 (59) months and 446 (72%) cases had
died (median [IQR] follow-up among the deceased was 17 [27] months). HRs increased with
increasing age (Table 1). No other demographic characteristic was associated with survival.
After adjustment for age, HRs were higher among cases who had bulbar onset, but lower
among those with longer diagnostic delays or higher baseline ALSFRS-R scores (Table 2). HRs
decreased with increases in time from diagnosis to Registry enrollment, but increased with
increases in time from Registry enrollment to GENEVA enrollment. Treatments associated
with poor condition at baseline (e.g., use of ventilator) had elevated HRs.
In weighted analyses, HRs were elevated among cases who served 1 year in the military
or before July 1950 (Table 3). Cases who were deployed to WWII or before July 1950 had
higher HRs than those who were not deployed (Table 4). There was a significant inverse trend
between end of most recent deployment and mortality (HR = 0.65; 95% CI: 0.48, 0.89),
although category-specific associations were not monotonic.
Table 5 presents weighted results for ever experiencing specific exposures during service or
deployment to the four wars; weighted results for analyses of exposure-response trends and
feeling ill after exposure are in Tables B-C in S1 File. For exposures experienced any time dur-
ing service, the HR for ever receiving anthrax vaccination was elevated but there was no expo-
sure-response trend nor was there an association with feeling ill after exposure. Survival was
not associated with ever taking pyridostigmine bromide pills, but HRs were elevated for taking
them more recently, on more total days, and for taking more total pills per day and overall;
however, all of these exposure-response metrics had fewer than five exposed deaths in some
categories. For exposures experienced during deployment to the four wars, HRs were elevated
for mixing and application of burning agents and there was a positive exposure-response
trend. In contrast, HRs were decreased for field exposure to riot control substances or burning
agents and the latter had an inverse exposure-response trend. HRs were elevated for high-
intensity radar wave exposure, being within one mile of any explosion, and feeling ill after any
explosion within one mile, but exposure-response trends were unapparent. HRs were lower
for exposure to: paint, solvents, or petrochemical substances; local food not provided by the
Armed Forces; hearing chemical alarms sounding; and Agent Orange, and the first three had
inverse exposure-response trends. Cases who felt ill after local food exposure also had lower
HRs than those who did not experience this exposure.
Sub-analyses restricted to veterans who were deployed to the Vietnam War generally
showed similar results (Tables D-G in S1 File) as did restricting to reduce sample heterogeneity
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Table 1. Demographic characteristics of amyotrophic lateral sclerosis deaths and total casesa in GENEVA, United States of America, 2005–2013.
Characteristic Deaths Total Crude Adjustedb
No. PMc No. PMc HRd 95% CId HRd 95% CId
Total 446 10,558 616 24,267
Age (years)
 39 17 409 42 2,470 0.60 0.36, 1.02
40–49 35 1,150 68 3,853 0.74 0.50, 1.09
50–59 117 2,893 171 7,186 1.00 Referent
60–69 165 3,624 203 6,708 1.45 1.14, 1.84
70–79 100 2,264 119 3,767 1.45 1.11, 1.90
> 79 12 219 13 283 1.98 1.09, 3.59
Median (IQR) 62 (14) 60 (14) 1.43e 1.26, 1.63e
Sex
Male 436 10,240 603 23,698 1.00 Referent 1.00 Referent
Female 10 318 13 569 1.00 0.53, 1.87 1.26 0.66, 2.39
Race/Ethnicity
Non-Hispanic White 413 9,491 561 21,419 1.00 Referent 1.00 Referent
Other 29 1,009 48 2,569 0.68 0.47, 1.00 0.74 0.51, 1.09
Missing 4 7
Use of VA health care system
No 254 5,920 361 14,502 1.00 Referent 1.00 Referent
Yes 192 4,639 254 9,686 1.04 0.86, 1.25 1.00 0.82, 1.21
Missing 0 1
Ever applied for VA benefits of any type
No 73 1,536 100 3,741 1.00 Referent 1.00 Referent
Yes 335 7,918 455 17,264 0.90 0.70, 1.16 0.92 0.71, 1.19
Missing 38 61
Highest degree attained
Grade school (grades 1–8) 17 496 20 753 1.22 0.74, 2.00 1.00 0.61, 1.66
High school diploma or other 191 4,455 266 10,474 1.00 Referent 1.00 Referent
Technical or vocation school diploma or Associate degree 81 1,604 114 4,207 0.95 0.73, 1.24 0.96 0.73, 1.25
College or graduate school diploma 145 3,692 199 8,152 0.98 0.79, 1.22 0.99 0.80, 1.24
Doctorate 12 310 17 681 0.88 0.49, 1.59 0.84 0.47, 1.52
Cigarette smoking status
Never 141 3,261 207 8,558 1.00 Referent 1.00 Referent
Past 232 5,531 305 11,380 1.13 0.92, 1.40 1.04 0.84, 1.29
Current 58 1,547 85 3,808 0.96 0.71, 1.31 1.02 0.75, 1.39
Missing 15 19
Abbreviations: ALS, amyotrophic lateral sclerosis; CI, confidence interval; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic
Lateral Sclerosis study; HR, hazard ratio; IQR, interquartile range; PM, person-months; VA, Department of Veterans Affairs.
a Fourteen ALS cases were excluded from this analysis because (1) they were missing data on diagnosis date (n = 7) or (2) they died before GENEVA
enrollment (i.e., enrollment was completed by proxy after the case died; n = 7).
b Adjusted for age (modeled with indicator variables corresponding to 5-year groups).
c Person-months calculated for time on study (i.e., the difference between the GENEVA enrollment date and the death date or July 25, 2013).
d HRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the GENEVA enrollment date.
e Scaled the HR to an IQR-unit increase in age among all cases.
https://doi.org/10.1371/journal.pone.0185751.t001
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Table 2. Clinical characteristics of amyotrophic lateral sclerosis deaths and total casesa in GENEVA,
United States of America, 2005–2013.
Characteristic Deaths Total Crude Adjustedb
No. PMc No. PMc HRd 95% CId HRd 95% CId
Most recent ALS diagnosis
category
Clinically definite 99 2,671 148 6,778 0.99 0.77, 1.26 1.04 0.81, 1.33
Clinically probable 232 5,140 311 11,522 1.00 Referent 1.00 Referent
Clinically possible 37 854 47 1,681 1.18 0.83, 1.67 1.22 0.86, 1.74
Suspected (progressive bulbar
palsy or progressive muscular
atrophy)
78 1,894 110 4,286 1.04 0.80, 1.35 0.98 0.76, 1.28
Symptom onset site
Bulbar 70 1,362 85 2,551 1.35 1.04, 1.75 1.23 0.94, 1.61
Extremities 352 8,586 499 20,512 1.00 Referent 1.00 Referent
Othere 23 579 31 1,171 0.84 0.55, 1.29 0.96 0.63, 1.48
Missing 1 1
Time from symptom onset to
diagnosis (months)
 6 90 2,299 116 4,483 0.85 0.65, 1.11 0.88 0.67, 1.15
> 6–12 138 2,868 166 5,041 1.00 Referent 1.00 Referent
> 12–18 73 1,434 104 3,869 0.74 0.56, 0.98 0.77 0.58, 1.03
> 18–24 36 799 46 1,617 0.88 0.61, 1.28 0.85 0.59, 1.24
> 24 104 2,940 172 8,426 0.56 0.43, 0.72 0.49 0.38, 0.64
Missing 5 12
Median (IQR) 11 (15) 13 (18) 0.82f 0.75, 0.91f 0.77f 0.70, 0.86f
Time from diagnosis to enrollment
in the Registry (months)
 12 185 3,372 216 5,699 1.00 Referent 1.00 Referent
> 12–24 116 2,838 142 4,865 0.95 0.74, 1.21 0.86 0.67, 1.11
> 24–36 47 1,091 75 3,347 0.76 0.53, 1.09 0.73 0.50, 1.05
> 36–48 26 643 44 2,071 0.83 0.51, 1.32 0.76 0.47, 1.23
> 48 72 2,614 139 8,284 0.73 0.44, 1.21 0.70 0.42, 1.17
Median (IQR) 15 (25) 19 (32) 0.82f 0.66, 1.03f 0.82f 0.65, 1.02f
Time from enrollment in the
Registry to enrollment in the
GENEVA study (months)
 6 140 2,795 178 5,634 0.99 0.78, 1.26 1.01 0.79, 1.30
> 6–12 142 3,101 204 8,157 1.00 Referent 1.00 Referent
> 12–18 72 1,951 95 3,896 1.36 1.02, 1.81 1.30 0.97, 1.74
> 18–24 51 1,526 71 3,286 1.34 0.96, 1.86 1.36 0.97, 1.90
> 24 41 1,186 68 3,294 1.31 0.90, 1.90 1.34 0.92, 1.95
Median (IQR) 9 (11) 9 (11) 1.16f 1.01, 1.34f 1.18f 1.02, 1.37f
Baselineg ALSFRS-R score
(possible range: 0–48)h
 16 108 2,071 133 4,167 1.87 1.41, 2.47 2.09 1.57, 2.77
> 16–23 94 1,815 116 3,674 1.50 1.13, 1.99 1.69 1.27, 2.25
> 23–30 99 2,730 137 5,787 1.00 Referent 1.00 Referent
> 30–35 77 1,792 111 4,466 0.88 0.65, 1.19 0.89 0.66, 1.21
> 35 68 2,151 119 6,172 0.53 0.39, 0.73 0.56 0.41, 0.76
Median (IQR) 26 (16) 27 (16) 0.54f 0.47, 0.62f 0.51f 0.44, 0.59f
Currently using riluzole (baselineg)
No 207 5,107 298 12,448 1.00 Referent 1.00 Referent
(Continued)
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Table 2. (Continued)
Characteristic Deaths Total Crude Adjustedb
No. PMc No. PMc HRd 95% CId HRd 95% CId
Yes 229 5,200 302 11,166 1.08 0.90, 1.31 1.14 0.94, 1.39
Missing 10 16
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CI,
confidence interval; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral
Sclerosis study; HR, hazard ratio; IQR, interquartile range; PM, person-months.
a Fourteen ALS cases were excluded from this analysis because (1) they were missing data on diagnosis
date (n = 7) or (2) they died before GENEVA enrollment (i.e., enrollment was completed by proxy after the
case died; n = 7).
b Adjusted for age (modeled with indicator variables corresponding to 5-year groups).
c Person-months calculated for time on study (i.e., the difference between the GENEVA enrollment date and
the death date or July 25, 2013).
d HRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the
GENEVA enrollment date.
e Includes “all over” (deaths: n < 5; total: n < 5), “cramps/fasciculations” (deaths: n = 18; total: n = 26), and
“loss of appetite” (deaths: n < 5; total: n < 5). Any numbers presented as “n < 5” were suppressed to preserve
the confidentiality of study participants.
f Scaled the HR and 95% CI to an IQR-unit increase in time from symptom onset to diagnosis, time from
diagnosis to enrollment in the Registry, time from enrollment in the Registry to enrollment in GENEVA, or
baseline ALSFRS-R score among all cases.
g The ALSFRS-R score or use status of riluzole that was measured closest to the time of GENEVA
enrollment (i.e., interview).
h Category boundaries were set at quintiles of the ALSFRS-R score among all cases.
https://doi.org/10.1371/journal.pone.0185751.t002
Table 3. Military service and amyotrophic lateral sclerosis survival in GENEVAa, United States of
America, 2005–2013.
Variable Deaths Total IP-weightedb
No. PMc No. PMc HRd 95% CId
Military branch of longest service
Air Force (including Army Air Force) 97 2,124 129 4,784 1.09 0.83, 1.44
Army 182 4,403 249 9,775 1.00 Referent
Marines (including Merchant Marines) 36 638 55 2,175 0.85 0.50, 1.43
Navy 98 2,570 136 5,616 0.87 0.65, 1.16
Othere 32 816 45 1,815 0.76 0.51, 1.13
Missing 1 2
Number of military branches of service
1 (Median = 1) 411 9,774 565 22,300 1.00 Referent
> 1 (2) 35 785 51 1,967 1.01 0.75, 1.38
Officer or Warrant Officer
No 373 8,685 514 20,110 1.00 Referent
Yes 72 1,858 100 4,060 0.96 0.72, 1.30
Missing 1 2
Years of military service
 1 (0.50) 13 241 15 400 1.80 1.11, 2.90
> 1–5 (2.92) 305 7,022 414 15,896 1.00 Referent
> 5–10 (7.92) 42 1,202 59 2,497 0.88 0.59, 1.31
> 10–15 (11.99) 14 436 26 1,398 0.80 0.48, 1.33
(Continued)
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Table 3. (Continued)
Variable Deaths Total IP-weightedb
No. PMc No. PMc HRd 95% CId
> 15–20 (18.92) 19 502 21 684 0.85 0.64, 1.11
> 20 (24.31) 52 1,147 79 3,290 1.02 0.71, 1.47
Missing 1 2
Trend (IQR = 6.00)f, g 1.00 0.91, 1.10
End of most recent period of military service (month/year)h
 12/1946 (03/1946) 26 593 32 1,073 1.58 0.96, 2.61
01/1947-06/1950 (02/1948) 9 185 11 341 2.23 1.06, 4.70
07/1950-01/1955 (06/1953) 48 1,332 56 2,003 1.04 0.71, 1.52
02/1955-02/1961 (12/1957) 78 1,648 97 3,266 1.18 0.83, 1.70
03/1961-07/1964 (06/1963) 34 849 43 1,603 1.04 0.66, 1.64
08/1964-04/1975 (07/1969) 134 3,160 192 7,732 1.00 Referent
05/1975-08/1980 (05/1978) 26 606 42 1,903 0.92 0.54, 1.56
09/1980-07/1990 (03/1986) 36 818 53 2,156 0.84 0.59, 1.21
08/1990-08/2001 (06/1994) 44 1,177 71 3,299 0.99 0.65, 1.49
> 08/2001 (10/2003) 10 182 17 789 0.94 0.48, 1.83
Missing 1 2
Trend (20 years, 11.99 months)f, g 0.98 0.81, 1.18
Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CI,
confidence interval; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral
Sclerosis study; HR, hazard ratio; IP, inverse probability; IQR, interquartile range; PM, person-months; VA,
Department of Veterans Affairs.
a Fourteen ALS cases were excluded from this analysis because (1) they were missing data on diagnosis
date (n = 7) or (2) they died before GENEVA enrollment (i.e., enrollment was completed by proxy after the
case died; n = 7).
b Weighted for confounding (conditional on age [modeled with indicator variables corresponding to 5-year
groups]), not missing baseline ALSFRS-R score (conditional on most recent ALS diagnosis category,
symptom onset site, diagnostic delay [months; modeled with the natural logarithm of a linear term], and time
from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic spline with knots
at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not
missing baseline ALSFRS-R score]), and participating in GENEVA (conditional on race/ethnicity, being a
current patient of a VA Medical Center, most recent ALS diagnosis category, symptom onset site, diagnostic
delay [months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the
Registry [months; modeled with a linear term], and baseline ALSFRS-R score [modeled with a restricted,
quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]).
95% CIs were calculated with robust variance estimates.
c Person-months calculated for time on study (i.e., the difference between the GENEVA enrollment date and
the death date or July 25, 2013).
d HRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the
GENEVA enrollment date.
e Includes Coast Guard (deaths: n = 6; total: n = 8), Activated National Guard (deaths: n = 5; total: n = 6),
Activated Reserves (deaths: n = 11; total: n = 17), Inactivated National Guard (deaths: n < 5; total: n < 5),
Inactivated Reserves (deaths: n = 8; total: n = 9), Department of Defense (deaths: n = 0; total: n = 0),
National Oceanic and Atmospheric Administration (deaths: n = 0; total: n < 5), and Public Health Service
(deaths: n = 0; total: n = 0). Any numbers presented as “n < 5” were suppressed to preserve the
confidentiality of study participants.
f Used within-category medians that were calculated using all cases.
g Scaled the HR to an IQR-unit increase in the exposure variable. IQRs were calculated using all cases.
h Category boundaries aligned with the occurrence of the major wars (e.g., the Vietnam War occurred
between August 1964 and May 1975) and followed Allen et al. [14], Beard et al. [17], and Schmidt et al. [15].
https://doi.org/10.1371/journal.pone.0185751.t003
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Table 4. Military deployments or danger pay and amyotrophic lateral sclerosis survival in GENEVAa, United States of America, 2005–2013.
Variable Deaths Total IP-weightedb
No. PMc No. PMc HRd 95% CId
Deployments
Ever deployed to any war/operatione
No 250 5,790 348 13,683 1.00 Referent
Yes 179 4,472 247 9,986 0.98 0.78, 1.23
Missing 17 21
War/operation of longest deploymente
Not deployed 250 5,790 348 13,683 1.00 Referent
World War II 24 671 29 1,076 1.97 1.34, 2.87
Korean War 29 686 32 931 0.96 0.41, 2.25
Vietnam War 98 2,318 138 5,474 1.02 0.75, 1.40
Gulf War < 5f 164 11 762 0.38 0.12, 1.18
Otherg 15 421 24 1,164 0.81 0.43, 1.54
Missing 26 34
Ever deployed to any other country
No 222 5,222 309 12,310 1.00 Referent
Yes 205 5,014 283 11,254 1.01 0.81, 1.26
Missing 19 24
Total time (years) of all periods of deployment to any war/
operatione
Not deployed (Median = 0.00) 250 5,790 348 13,683 1.00 Referent
 1 (0.67) 88 2,206 120 4,834 1.10 0.86, 1.41
> 1–2 (1.25) 45 1,228 67 2,918 0.77 0.56, 1.06
> 2–4 (2.37) 29 643 36 1,238 1.45 1.01, 2.10
> 4 (6.00) 8 183 11 417 0.64 0.19, 2.23
Missing 26 34
Trendh 0.87 0.71, 1.07
End of most recent period of deployment to any war/operation
(month/year)e, i
Not deployed 250 5,790 348 13,683 1.00 Referent
 06/1950 (01/1946) 23 656 28 1,061 1.74 1.16, 2.60
07/1950-01/1955 (01/1953) 24 539 26 702 1.35 0.90, 2.03
02/1955-02/1961 (02/1956) 7 165 8 247 1.94 0.48, 7.75
03/1961-04/1975 (02/1969) 98 2,362 136 5,348 1.14 0.82, 1.58
05/1975-07/1990 (08/1980) 6 147 10 491 1.00 0.53, 1.87
> 07/1990 (07/1992) 12 391 25 1,462 0.58 0.30, 1.10
Missing 26 35
Trend (IQR = 14 years, 11.98 months)h, j 0.65 0.48, 0.89
Danger pay, hardship duty or combat zone tax exclusion
benefits for deployment
Ever received imminent danger pay, hardship duty or combat
zone tax exclusion benefits for deployment
No 309 7,571 414 16,134 1.00 Referent
Yes 103 2,267 157 6,498 0.87 0.66, 1.15
Missing 34 45
Total time (years) of all periods of deployment to any countries or
sea region(s) ever received imminent danger pay, hardship duty or
combat zone tax exclusion benefits for deployment
(Continued )
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(Table H in S1 File), control confounding by sex, or mitigate potential bias from exposure mis-
classification. Using age as the timescale, with late entry at GENEVA enrollment date, pro-
duced similar results. Recoding implausible values to missing for exposures that had distinct
time periods of use removed the association between anthrax vaccination and shorter survival
(HR = 0.99; 95% CI: 0.43, 2.26), but gave qualitatively similar results for the other three expo-
sures. The majority of exposures were either not or only weakly correlated (absolute value of
coefficients 0.2), and results were similar after mutually-adjusting correlated exposures.
Finally, adjusting for potential confounding via standard regression methods, but without
Table 4. (Continued)
Variable Deaths Total IP-weightedb
No. PMc No. PMc HRd 95% CId
Never received imminent danger pay, hardship duty or combat
zone tax exclusion benefits for deployment (0.00)
309 7,571 414 16,134 1.00 Referent
 1 (0.83) 47 1,092 73 3,104 0.80 0.52, 1.21
> 1–2 (1.13) 21 447 30 1,172 0.88 0.58, 1.33
> 2 (2.50) 8 191 11 462 1.00 0.48, 2.07
Missing 61 88
Trendh 0.98 0.79, 1.22
Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CI, confidence interval; GENEVA, Genes and
Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis study; Gulf, 1990–1991 Persian Gulf; HR, hazard ratio; IP, inverse probability;
IQR, interquartile range; PM, person-months; VA, Department of Veterans Affairs.
a Fourteen ALS cases were excluded from this analysis because (1) they were missing data on diagnosis date (n = 7) or (2) they died before GENEVA
enrollment (i.e., enrollment was completed by proxy after the case died; n = 7).
b Weighted for confounding (conditional on age [modeled with indicator variables corresponding to 5-year groups]), not missing baseline ALSFRS-R score
(conditional on most recent ALS diagnosis category, symptom onset site, diagnostic delay [months; modeled with the natural logarithm of a linear term], and
time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months
based on percentiles of the distribution in the Registry cases not missing baseline ALSFRS-R score]), and participating in GENEVA (conditional on race/
ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis category, symptom onset site, diagnostic delay [months; modeled with
linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score
[modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]). 95% CIs were
calculated with robust variance estimates.
c Person-months calculated for time on study (i.e., the difference between the GENEVA enrollment date and the death date or July 25, 2013).
d HRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the GENEVA enrollment date.
e The GENEVA study questionnaire asked "Were you deployed to. . ." the following wars where each war was asked about with a separate question: World
War II (defined as the period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31,
1955), the Vietnam War (defined as the period from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990,
to December 31, 1991) [16]. The questionnaire also asked "Ever deployed. . ." to the following countries where each country was asked about with a
separate question: Grenada, Lebanon, Panama, Somalia, Bosnia, Kosovo, Rwanda, Afghanistan, and Iraq/Persian Gulf region (Gulf War II) [16].
f Suppressed to preserve the confidentiality of study participants.
g Includes Grenada (deaths: n = 0; total: n = 0), Lebanon (deaths: n < 5f; total: n = 5), Panama (deaths: n < 5f; total: n = 8), Somalia (deaths: n < 5f; total:
n < 5f), Bosnia (deaths: n < 5f; total: n < 5f), Kosovo (deaths: n = 0; total: n = 0), Rwanda (deaths: n = 0; total: n = 0), Afghanistan (deaths: n < 5f; total: n < 5f),
and Iraq/Persian Gulf region (Gulf War II) (deaths: n = 5; total: n = 6).
h Used within-category medians that were calculated using all cases.
i Category boundaries aligned with the occurrence of the major wars (e.g., the Vietnam War occurred between August 1964 and May 1975) and followed
Allen et al. [14], Beard et al. [17], and Schmidt et al. [15].
j Scaled the HR to an IQR-unit increase in the exposure variable. IQRs were calculated using all cases except those in the reference category. Reference
category excluded for linear trend test.
https://doi.org/10.1371/journal.pone.0185751.t004
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Table 5. Military exposures and amyotrophic lateral sclerosis survival in GENEVAa, United States of America, 2005–2013.
Exposure Deaths Totalb IP-weightedc, d
No. PMe No. PMe HRf 95% CIf
Total 446 10,558 616 24,267
Ever received the anthrax vaccine prior to reference date 25 534 35 1,372 1.62 1.10, 2.40
Ever received the smallpox vaccine 329 7,944 454 18,127 0.92 0.67, 1.26
Prior to reference date, ever involved in testing, transporting or
spraying herbicides for military purposes
10 350 17 851 1.12 0.63, 1.99
Prior to reference date, ever been treated with nasopharyngeal (NP)
radium during military service
< 5g 96 < 5g 179 0.97 0.59, 1.59
Ever taken pyridostigmine bromide, or little white pills in foil packs,
sometimes called NAPPs, which are used to protect against nerve
agents
10 296 18 940 1.21 0.42, 3.44
Prior to reference date, ever visited or resided in the island of Guam,
the islands of New Guinea, or the Kii Peninsula of Japan (including
any time spent there in the military)
66 1,619 90 3,550 1.00 0.76, 1.30
While you were in WWII, the Korean War, the Vietnam War, or
the Gulf Warh: did you have direct contact with/were you
exposed to
168 4,112 228 8,976
Ionizing radiation from nuclear weapon testing or occupation of
Hiroshima/Nagasaki
< 5g 18 < 5g 77 1.01 0.22, 4.75
Use of personal pesticides, like creams, sprays or flea collars 50 1,206 67 2,536 0.91 0.62, 1.33
Use of pesticides on your clothing or bedding 36 675 49 1,673 1.05 0.63, 1.77
Exhaust from heaters or generators (e.g., kerosene heaters, tent
heaters)
52 1,213 74 3,035 0.81 0.53, 1.21
Exposure to diesel and/or other petrochemical fumes 102 2,499 143 5,750 1.06 0.66, 1.72
Burning trash or burning feces/manure 51 1,243 74 3,096 0.80 0.54, 1.19
Exposure to paint, solvents, or petrochemical substances 45 1,132 72 3,264 0.73 0.50, 1.06
High-intensity radar waves (e.g., as radar operator, radio
operator, aviation electrician’s mate)
35 815 46 1,692 1.32 0.91, 1.92
Food contaminated with smoke, oil, or other chemicals 11 267 15 580 0.71 0.36, 1.40
Local food other than food provided by the Armed Forces 77 2,056 112 4,873 0.68 0.49, 0.93
Bathing in or drinking of water contaminated with smoke, oil, dead
animals or any chemicals
12 188 20 801 0.85 0.33, 2.21
Heat cramps, heat exhaustion, heat stroke or other heat Illness 34 811 50 2,103 0.88 0.54, 1.44
Heard chemical alarms sounding 7 169 15 810 0.59 0.25, 1.40
Explosion in the air or on the ground within one mile of you (e.g.,
artillery, rockets, mortars)
112 2,601 149 5,597 1.27 0.87, 1.84
Have you suffered a combat-related injury that required medical
attention during your deployment?
38 1,015 49 1,871 0.88 0.54, 1.44
While you were in WWII, the Korean War, or the Vietnam Warh:
did you have direct contact with/were you exposed to
164 3,992 216 8,164
Mixing and application of herbicides < 5g 87 < 5g 87 1.57 0.99, 2.51
Exposure to herbicides in the field 10 304 11 396 1.02 0.62, 1.66
Mixing and application of riot control substances < 5g 9 < 5g 9 4.30 2.33, 7.94
Exposure to riot control substances in the field 9 267 12 490 0.63 0.32, 1.21
Mixing and application of burning agents 13 193 14 284 2.57 1.28, 5.12
Exposure to burning agents in the field 22 511 32 1,271 0.56 0.35, 0.91
While you were in the Korean War, the Vietnam War, or the Gulf
Warh: did you have direct contact with/were you exposed to
141 3,384 194 7,659
Microwave radiation 10 241 14 581 1.03 0.62, 1.69
While you were in the Vietnam Warh: did you have direct
contact with/were you exposed to
104 2,492 145 5,739
(Continued )
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weighting for potential missing-covariate-data or selection bias, gave results that were gener-
ally similar (“Adjusted” columns, Tables B-G and I-K in S1 File).
Discussion
We found shorter survival among cases who served 1 year in the military, served or were
deployed before July 1950 or in WWII, and mixed and applied burning agents. In contrast,
Table 5. (Continued)
Exposure Deaths Totalb IP-weightedc, d
No. PMe No. PMe HRf 95% CIf
Mixing and application of Agent Orange 6 127 8 283 0.62 0.32, 1.20
Exposure to Agent Orange in the field 39 795 63 2,668 0.66 0.42, 1.05
While you were in the Gulf Warh: did you have direct contact
with/were you exposed to
8 289 16 980
Use of depleted uranium (DU) for munitions or armor < 5g 43 5 389 0.61 0.15, 2.41
CARC (Chemical Agent Resistant Compound) paint < 5g 69 < 5g 240 1.78 0.36, 8.94
Scud missile explosion in the air or on the ground within one mile
of you
< 5g 78 < 5g 267 3.84 0.82, 18.00
Smoke from oil well fires < 5g 68 9 665 0.25 0.06, 1.02
Exposure to nerve gas (e.g., during munitions destruction) 0 0 < 5g 281 i i
High levels of dust/sand 5 202 13 894 0.15 0.01, 1.56
Ground level fumigation 0 0 < 5g 365 i i
In any conflicts deployed to, any other exposure or experience not
asked about which you consider harmful or extremely stressful
52 1,420 68 2,692 0.79 0.52, 1.21
Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CARC, Chemical Agent Resistant Compound; CI,
confidence interval; DU, depleted uranium; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis study; Gulf,
1990–1991 Persian Gulf; HR, hazard ratio; IP, inverse probability; NP, nasopharyngeal; PM, person-months; VA, Department of Veterans Affairs; WWII,
World War II.
a Fourteen ALS cases were excluded from this analysis because (1) they were missing data on diagnosis date (n = 7) or (2) they died before GENEVA
enrollment (i.e., enrollment was completed by proxy after the case died; n = 7).
b Information for specific exposures was missing for 0–49% of cases.
c Cases who did not experience direct contact with each specific exposure were the reference.
d Weighted for confounding (conditional on age [modeled with indicator variables corresponding to 5-year groups or, for exposures queried only in reference
to deployment to the Gulf War, modeled with a linear term that was centered at 60—the median among all cases] and war/operation of longest deployment),
not missing baseline ALSFRS-R score (conditional on most recent ALS diagnosis category, symptom onset site, diagnostic delay [months; modeled with
the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic spline with knots
at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing baseline ALSFRS-R score]), and
participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis category, symptom onset
site, diagnostic delay [months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a
linear term], and baseline ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution
in GENEVA cases]). 95% CIs were calculated with robust variance estimates.
e Person-months calculated for time on study (i.e., the difference between the GENEVA enrollment date and the death date or July 25, 2013).
f HRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the GENEVA enrollment date.
g Suppressed to preserve the confidentiality of study participants.
h The GENEVA study questionnaire asked "Were you deployed to. . ." the following wars where each war was asked about with a separate question: World
War II (defined as the period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31,
1955), the Vietnam War (defined as the period from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990,
to December 31, 1991) [16].
i Unable to estimate HR and 95% CI.
https://doi.org/10.1371/journal.pone.0185751.t005
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survival was longer among cases who were exposed to: paint, solvents, or petrochemical sub-
stances; local food not provided by the Armed Forces; or burning agents and Agent Orange in
the field. We obtained similar results from several secondary analyses, such as restricting to
cases who: enrolled within two years of diagnosis; had definite or probable ALS; were men; or
did not need a proxy interview.
Some evidence suggests ALS diagnoses may be increased among military veterans, particu-
larly those deployed to the Gulf War [7–10]. However, few studies have evaluated associations
between military-related or other environmental or occupational factors and ALS progression
or survival, and they all have important limitations [4–6, 11, 12]. The study based on the ALS
Clinical Assessment, Research and Education database [11] was published in abstract form
only, so it is difficult to evaluate. The Massachusetts study [6], which also reported no associa-
tion between one-year disease progression and exposure to several toxicants evaluated as a
group, did not adjust for age at diagnosis, which is one of the most consistently reported prog-
nostic factors for ALS survival [2–5]. This limitation is shared by a study in Italy which found
agricultural work was not associated with cumulative or one-year survival [4]. The studies by
Kasarskis et al. [12] and Pastula et al. [5], which examined war deployments, were susceptible
to immortal person-time bias. The discrepant results of these studies may be because the first
—which found a positive association—was restricted to Gulf War-era veterans [12], whereas
the other—which found no association—included non-Gulf War-era veterans [5]. Like Pastula
et al. [5], our study included a subset of Registry cases who served as far back as WWII. Unlike
Pastula et al. [5], we found shorter survival among cases who were deployed to WWII, but not
to other wars/operations, compared to non-deployed cases.
Our finding of an association between anthrax vaccination and shorter survival may be
partly due to reporting errors; some veterans who reported receiving the vaccination served in
the military in the 1950s [17], but the vaccination was not available until 1998 [46]. Recoding
implausible values to missing removed the association. Our finding of shorter survival among
cases who mixed and applied burning agents contrasts with the longer survival we observed
among cases who experienced field exposure to burning agents. Mixing and applying, how-
ever, may have resulted in greater exposure than field exposure and was also likely less suscep-
tible to recall bias. Our finding of positive exposure-response trends between pyridostigmine
bromide pills and survival was limited by small numbers of deaths in exposure categories and
should be interpreted cautiously. The elevated HR observed for high-intensity radar waves is
consistent with reports that non-ionizing radiation may be associated with ALS etiology [47].
One explanation for associations we observed between longer survival and exposure to: paint,
solvents, or petrochemical substances; local food; or Agent Orange in the field is individuals
who were susceptible to these exposures may have died before Registry enrollment. However,
we found no relationship between these exposures and diagnostic delay, symptom onset site,
or baseline ALSFRS-R score, which were clinical factors consistently reported to be associated
with shorter survival by previous studies [2–6].
Residual confounding by age may have affected our results because cases who served before
July 1950 or were deployed to WWII were more than 70 years-old in 2005–2010 when
GENEVA was conducted [15] and were thus more likely to die during follow-up. Using age as
the timescale, with late entry at GENEVA enrollment date, however, gave similar results. It is
also possible other exposures experienced during military service or civilian life confounded
associations we observed between survival and specific exposures experienced during deploy-
ment to the four wars. We did not adjust for non-military exposures, but results were similar
after mutually-adjusting correlated military exposures, which mitigates this concern.
The positive association we observed between ALS survival and time from enrollment in
the Registry to enrollment in GENEVA is perplexing. This result was meant to be descriptive
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and, therefore, was adjusted for age at diagnosis via standard regression methods, but was not
weighted for potential missing-covariate-data or selection biases. It is possible that this result is
due to selection bias. In other words, it is possible that the patients with the fastest progressing
ALS died after they enrolled in the Registry, but before they enrolled in GENEVA (Table A in
S1 File). This would create the appearance of a positive association between ALS survival and
time from enrollment in the Registry to enrollment in GENEVA among ALS cases who
enrolled in GENEVA.
The four assumptions for using weights for analysis are consistency, exchangeability (i.e.,
no unmeasured confounding, missing data, or selection bias), no misspecification of models
used to estimate the weights, and positivity [31]. Consistency is not empirically verifiable, but
is often assumed to hold [31]. As described above, we explored exchangeability by conducting
secondary analyses in which we restricted to men only and mutually-adjusted correlated mili-
tary exposures. We attempted to minimize model misspecification by using the Akaike Infor-
mation Criterion [48] to select the form (e.g., linear, categorical, spline, etc.) for each
continuous variable included in our models for the weights [49] (Section C in S1 File). To
explore positivity, we created cross-tabulations of the military-related factors and age and war/
operation of deployment (for military exposures).
We also inspected appropriateness of the weights we used in our analyses. Most means of
the overall stabilized weights were near one and there were few extreme weights. Exceptions
generally occurred among time-related variables (e.g., end of most recent service or deploy-
ment). Cross-tabulations of the affected variables and age revealed empty cells—especially in
extreme combinations of the variables and age. These instances of empty cells are likely struc-
tural rather than random [31], because, for example, WWII veterans would not have
been 39 years-old when GENEVA was conducted. We remedied the problem by collapsing
categories of both the affected variables and age and obtained HRs and 95% CIs that were simi-
lar to those we obtained when we used the expanded versions.
Our results do not generalize to veteran cases who died before enrollment in the Registry
began in 2003 [5] or who did not join the Registry for other reasons [17] because we were only
able to weight GENEVA cases to represent Registry cases. In addition, the median (IQR) time
from enrollment in the Registry to enrollment in GENEVA was nine (11) months, which is a
short interval relative to elapsed time since diagnosis for cases who were long-term survivors.
Thus, our results could have been affected by residual selection bias.
There are limitations to studying cases from the Registry. For example, the Registry con-
tains incident cases and prevalent cases that include some long-term survivors [15, 50]. In
addition, as among non-deployed veterans in the VA’s previous Gulf War ALS study [8, 10],
the Registry likely under-ascertained cases [17] notwithstanding a national recruiting effort
[14]. Despite these limitations, we observed associations between clinical and demographic
characteristics and ALS survival that agreed with previous literature—e.g., HRs for death
decreased with increases in diagnostic delay [2, 5, 6] and baseline ALSFRS-R score [2, 3] and
were higher among older cases [2–5]—increasing confidence in our results.
We collected information on military-related factors via standardized telephone inter-
views [15, 16] because of the lack of suitable exposure biomarkers and sufficiently detailed
military databases for most exposures we evaluated in our study [17]. Several studies have
evaluated the validity and reliability of many self-reported military-related factors, usually in
comparison to data from the U.S. Department of Defense’s Defense Manpower Data Center,
and reported concordances to range from “moderate” (e.g., κ = 0.41–0.60) to “almost per-
fect” (e.g., κ> 0.80) [10, 46, 51–58]. Validity studies evaluated deployment status and fre-
quency, number, and start dates of deployment(s) [10, 56]; occupational titles [57]; and
anthrax [46, 54] or smallpox vaccination [53]. Military-related factors evaluated in reliability
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studies included combat-related experiences, exposures, or traumatic events [51, 52, 55, 58]
and exposure indices constructed by averaging or summing participants’ answers for spe-
cific items [51, 52, 55, 58]. Unfortunately, none of these studies assessed the validity or reli-
ability of self-reported military-related factors extending back to WWII (the longest time
between exposure and assessment of exposure in these studies was about 10 years [10]) or
whether the quality of self-report fluctuated by time period of service or war/operation of
deployment.
Although the validity and reliability of self-report has not been determined for many of the
military-related factors we evaluated in our study, we would typically expect military service
factors, such as branch of service or rank, to be more validly and reliably reported than military
deployment factors, such as war/operation of deployment or dates of deployment, which
would likely be more validly and reliably reported than specific military exposures [17]. In
fact, this is the pattern typically described by other occupational epidemiology studies (i.e., job
title is typically more validly and reliably reported than dates of employment or job tasks,
which are typically more validly and reliably reported than specific occupational exposures)
[59].
Strategies to improve recall for GENEVA included asking participants about exposures that
can be sensed (e.g., heard chemical alarms sounding), using general terms (e.g., flea collar
rather than specific pesticides), querying a list of specific exposures, and providing bench-
marks against which respondents could compare their exposure levels (e.g., feeling ill after
exposure) [15]. Despite using these strategies, we found some reporting errors for a few expo-
sures with distinct time periods of use. When we set implausible values to missing, however,
results were qualitatively similar for exposures other than anthrax vaccination. Importantly,
results were similar after restricting to non-proxy interviews.
Strengths of our study include medical record-confirmed diagnoses and relatively complete
ascertainment of deaths from VA sources. We also had a large sample size, although the num-
ber of deceased cases who experienced some exposures, particularly Gulf War-specific ones,
was small. We had extensive information on military service, deployments, and 39 related
exposures. Given the large number of exposures for which we evaluated associations with ALS
survival and the hypothesis-generating nature of our study, it is possible that some of the asso-
ciations we observed may not be true. However, we obtained similar results from sub-analyses
that created a more homogeneous sample or attempted to reduce potential biases. Finally, we
used inverse probability weights to explore and control potential biases from confounding,
missing covariate data, and selection among a case group that included a disproportionate
number of long-term survivors at enrollment.
Conclusions
In conclusion, this is one of the first and largest studies, and the most complete, to date of ALS
survival and non-clinical factors—specifically those related to military service. It includes both
detailed exposure assessment and sophisticated analytic approaches to minimize bias.
Although we observed associations with clinical and demographic characteristics that agreed
with previous literature, most military-related factors were not associated with ALS survival.
Associations we observed between shorter survival and certain exposures, such as burning
agents, although novel and needing confirmation, are potentially important because of the
large number of U.S. military veterans. Furthermore, they could help clinicians target inter-
ventions that may have the potential to lengthen survival among patients at greatest risk of
shorter survival.
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